Monomethyl Auristatin E: A Potent Cytotoxic Agent in Cancer Therapeutics and Radiosensitization
Unlocking advanced cancer treatment through targeted drug conjugates and radiation synergy.
Get a Quote & SampleProduct Core Value
Monomethyl Auristatin E
Monomethyl Auristatin E (MMAE) is a potent synthetic antimitotic agent derived from the natural product Dolastatin 10. It functions by inhibiting tubulin polymerization, a critical process for cell division, leading to cell cycle arrest and eventual apoptosis. While MMAE is too toxic for direct clinical use, its precise mechanism of action makes it an invaluable component in targeted cancer therapies.
- Discover the potent cytotoxic mechanism of MMAE for targeted cancer treatment, a key component in advanced therapies.
- Explore how MMAE functions as a radiosensitizer, amplifying the effectiveness of radiation therapy against tumors.
- Learn about the role of MMAE in Antibody-Drug Conjugates (ADCs) and Peptide Drug Conjugates (PDCs) for precise tumor-directed cytotoxicity.
- Understand the potential of MMAE in trimodal cancer therapy, combining chemotherapy, radiotherapy, and immunotherapy for enhanced outcomes.
Product Advantages
Targeted Cytotoxicity
MMAE's high potency allows for targeted delivery via ADCs, minimizing damage to healthy tissues and enhancing therapeutic efficacy in cancer treatment.
Synergistic Radiosensitization
MMAE enhances the effects of radiation therapy by increasing DNA damage, leading to improved tumor control when used in combination.
Immune System Modulation
The combination of MMAE and radiation can stimulate anti-tumor immune responses, potentiating the effects of immune checkpoint inhibitors for durable tumor control.
Key Applications
Cancer Therapy Development
Utilized in the development of next-generation antibody-drug conjugates (ADCs) and peptide drug conjugates (PDCs) for targeted cancer treatment.
Combination Treatment Strategies
Investigated for its synergistic effects with radiation therapy and immunotherapy, forming the basis for trimodal cancer treatment approaches.
Oncology Research
A critical tool in preclinical research for understanding tumor biology, drug mechanisms, and developing novel cancer treatment modalities.
Preclinical Drug Discovery
Essential for evaluating the efficacy and safety of novel targeted therapies, particularly in the context of radiosensitization and immune response.
Related Technical Articles & Resources
Why Choose Us?
Leverage our expertise and state-of-the-art infrastructure to accelerate your journey from discovery to commercial success.
Global Experience
With 20 years of R&D, manufacturing, and sales experience, we proudly serve clients across 60 countries and regions worldwide.
Advanced Facilities
Our in-house R&D laboratory, pilot platform, and large-scale production workshop are equipped to meet the audit requirements of global customers.
Seamless Scalability
We facilitate a perfect transition from small-scale lab requirements (grams) to full commercialization (hundreds of tons).